A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

NCT04876391 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa

Interventions

DRUG: Spesolimab 1200 mg
DRUG: Spesolimab 600 mg
DRUG: Placebo matching 600 mg Spesolimab
DRUG: Placebo matching 1200 mg Spesolimab

Sponsor

Boehringer Ingelheim